An Organofluorine Isoselenocyanate Analogue of Sulforaphane Affects Antimetabolite 5-Fluorouracil’s Anticancer Activity: A Perspective for New Combinatory Therapy in Triple-Negative Breast Cancer
Molecules · 2023
DOI: 10.3390/molecules28155808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Małgorzata Milczarek und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Translation Research, Department of Biomedical Research, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland. Hauptthemen laut MEDLINE: Antineoplastic Agents, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Polish Ministry of Science and Higher Education.
Abstract (Originalsprache)
Antimetabolites, especially 5-fluorouracil, are commonly used clinically to treat breast, colon, and other cancers. However, their side effects and inefficiency in monotherapy have prompted further searches for new combinations. Thus, the anticancer effect of 5-fluorouracil (5-FU) and the sulforaphane analogue, 4-isoselenocyanato-1-butyl 4′-fluorobenzyl sulfoxide (ISC), were tested in in vitro and in vivo models of triple-negative breast cancer (TNBC) as a new option for this treatment-resistant and aggressive type of breast cancer. A synergic interaction between 5-FU and ISC was observed in the TNBC in vitro model MDA-MB-231 cell line, which led to enhanced antiproliferative effects. The results of in vitro studies were confirmed by in vivo tests, which demonstrated stronger tumor growth inhibition and additive interactions between 5-FU and ISC in the murine TNBC model. Moreover, the results of the body mass and blood analysis showed the safety of the tested combination. The mechanistic study revealed that the combined treatment triggered apoptosis and necrosis, as well as inhibited cell migration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Translation Research, Department of Biomedical Research, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland.
- Division of Organic Chemistry, Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Sienkiewicza 112, 90-363 Łódź, Poland.
- Department of Laboratory Medicine, Medical University of Warsaw, Stefana Banacha 1A, 02-097 Warsaw, Poland.
- Central Laboratory, Central Teaching Hospital University Clinical Center, Medical University of Warsaw, Stefana Banacha 1A, 02-097 Warsaw, Poland.
- Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla 12, 53-114 Wrocław, Poland.
- Faculty of Chemistry, University of Warsaw, Ludwika Pasteura 1, 02-093 Warsaw, Poland.
ORCID-Profile: Małgorzata Milczarek, Milena Małecka-Giełdowska, Joanna Wietrzyk, Maciej Mazur, Katarzyna Wiktorska
Förderung
- Polish Ministry of Science and Higher Education
Zitieren
APA
Milczarek, M., Cierpiał, T., Kiełbasiński, P., Małecka-Giełdowska, M., Świtalska, M., Wietrzyk, J., Mazur, M., & Wiktorska, K. (2023). An Organofluorine Isoselenocyanate Analogue of Sulforaphane Affects Antimetabolite 5-Fluorouracil’s Anticancer Activity: A Perspective for New Combinatory Therapy in Triple-Negative Breast Cancer. Molecules. https://doi.org/10.3390/molecules28155808
Vancouver
Milczarek M, Cierpiał T, Kiełbasiński P, Małecka-Giełdowska M, Świtalska M, Wietrzyk J, et al. An Organofluorine Isoselenocyanate Analogue of Sulforaphane Affects Antimetabolite 5-Fluorouracil’s Anticancer Activity: A Perspective for New Combinatory Therapy in Triple-Negative Breast Cancer. Molecules. 2023. doi:10.3390/molecules28155808
BibTeX
@article{Milczarek2023,
author = {Milczarek, Małgorzata and Cierpiał, Tomasz and Kiełbasiński, Piotr and Małecka-Giełdowska, Milena and Świtalska, Marta and Wietrzyk, Joanna and Mazur, Maciej and Wiktorska, Katarzyna},
title = {An Organofluorine Isoselenocyanate Analogue of Sulforaphane Affects Antimetabolite 5-Fluorouracil’s Anticancer Activity: A Perspective for New Combinatory Therapy in Triple-Negative Breast Cancer},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28155808}
}
EUVIMED